Wave Life Sciences

Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

New York, Dec. 26, 2025 (10:08 a.m. ET) — Wave Life Sciences Ltd. (NASDAQ: WVE) is trading at $18.12, down about 0.74% in the late morning session. The move comes while biotech is broadly softer—SPDR S&P Biotech ETF (XBI) is

26 December 2025

Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences Ltd. (NASDAQ: WVE) is ending 2025 as one of biotech’s most watched “story stocks”—the kind that can go from sleepy to screaming in a single premarket headline, then spend weeks digesting what just happened. On December 24,

24 December 2025

Analyst Forecasts · Biotechnology · Financial Analysis · Investment News · Stock Market

Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences Ltd. (NASDAQ: WVE) is back in the spotlight on December 18, 2025—not because of a brand-new press release, but because the stock is still digesting one of the most volatile biotech weeks of the year. In Thursday

18 December 2025

Analyst Ratings · Biotech Stocks · Investment Insights · NASDAQ:WVE · Obesity Treatments · Stock Market News

Wave Life Sciences (WVE) Stock News Today: Oppenheimer Lifts Target to $32 as WVE-007 Obesity Data Fuels Volatility

December 16, 2025 — Wave Life Sciences Ltd. (NASDAQ: WVE) is back in the spotlight after a roller-coaster week that mashed together three classic biotech ingredients: eye-popping early clinical data, a rapidly upsized stock offering, and a stack of Wall

16 December 2025

Biotechnology · Financial News · Investing · Obesity Research · Stock Market

Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Updated: December 11, 2025 – all figures and ratings as of publication; this article is for information only and is not investment advice. Key takeaways WVE stock today: from under‑the‑radar biotech to market spotlight Wave Life Sciences Ltd. (NASDAQ: WVE),

11 December 2025

Analyst Ratings · Biotechnology · NASDAQ:WVE · Obesity Research · Pharmaceutical Industry · Stock Market

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences Ltd. (NASDAQ: WVE) has suddenly gone from sleepy small‑cap biotech to front‑page obesity contender. After unveiling striking Phase 1 data for its RNA obesity drug WVE‑007 on December 8, 2025, the stock rocketed roughly 147% to about

9 December 2025

Biotechnology · Investment News · NASDAQ:WVE · NYSE:NVO · Obesity Treatment · Pharmaceutical Industry · Stock Market

Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences Ltd. (NASDAQ: WVE) just delivered one of the wildest biotech moves of 2025. On Monday, December 8, 2025, the stock rocketed after the company reported positive Phase 1 obesity drug data for WVE‑007 and simultaneously launched a

9 December 2025

Biotech · Investing · NASDAQ:WVE · Obesity Treatments · Pharmaceutical News · Stock Market

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Published: December 8, 2025 WVE stock more than doubles on massive volume Wave Life Sciences Ltd. (NASDAQ: WVE) staged a spectacular rally on Monday after unveiling positive interim data from its Phase 1 INLIGHT trial for obesity drug candidate WVE‑007.

8 December 2025

Biotechnology · Investment · NASDAQ:WVE · Obesity · Stocks · Wall Street